KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Minority Interest (2023 - 2025)

Edwards Lifesciences has reported Minority Interest over the past 3 years, most recently at $61.2 million for Q2 2025.

  • Quarterly results put Minority Interest at $61.2 million for Q2 2025, down 8.93% from a year ago — trailing twelve months through Jun 2025 was $61.2 million (down 8.93% YoY), and the annual figure for FY2024 was $64.5 million, down 7.06%.
  • Minority Interest for Q2 2025 was $61.2 million at Edwards Lifesciences, down from $62.9 million in the prior quarter.
  • Over the last five years, Minority Interest for EW hit a ceiling of $84.0 million in Q1 2023 and a floor of $61.2 million in Q2 2025.
  • Median Minority Interest over the past 3 years was $67.8 million (2024), compared with a mean of $68.4 million.
  • Peak annual rise in Minority Interest hit 5.08% in 2024, while the deepest fall reached 18.45% in 2024.
  • Edwards Lifesciences' Minority Interest stood at $69.4 million in 2023, then dropped by 7.06% to $64.5 million in 2024, then decreased by 5.12% to $61.2 million in 2025.
  • The last three reported values for Minority Interest were $61.2 million (Q2 2025), $62.9 million (Q1 2025), and $64.5 million (Q4 2024) per Business Quant data.